Currently, umbilical cord blood hematopoietic stem cells are one of the important sources of clinical stem cells. Compared with bone marrow and peripheral blood, cord blood has high clinical value and significant effect in the treatment of malignant diseases such as leukemia, neuroblastoma, and lymphoma. And when the cord blood hematopoietic stem cells were used for treatment, the side effects and exclusion is also lower, if for the autologous use, it definitely will not produce side effects and exclusion. Therefore, for cord blood, it is more useful to make it preserved
Umbilical cord blood transplantation has gone through 30 years since the first case was developed. The clinical cases oftransplantation based on cord blood-derived hematopoietic stem cells all over the world have been increasing year by year. The latest data show that more than 50,000 cases of cord blood transplantation have been conducted worldwide.
It is known that the value of cord blood in clinical autologous application is officially recognized. In China, the umbilical cord blood transplantation has been defined explicitly by National Health and Family Planning Commission of the People‘s Republic of China as a medical technology that allows to applied clinically. In February 2017, The Technology Management standard of Hematopoietic Stem Cell Transplantation (2017 Edition) issued by Health and Family Planning Commission clearly define that cord blood hematopoietic stem cell
transplantation is suitable for the treatment of acute leukemia, chronic leukemia, myelodysplastic syndromes and other malignant diseases such as multiple myeloma, lymphoma, and certain other malignancies; and non-malignant diseases such as aplastic anemia, severe radiation sickness, and severe thalassemia; as well as some genetic diseases, congenital diseases, and metabolic diseases.
At present, cord blood hematopoietic stem cells have been applied to the treatment for more than 80 diseases worldwide and there are nearly 400 clinical trials used cord blood and registered and ongoing on ClinicalTrials, and the number is still climbing.
It is now certain that cord blood hematopoietic stem cells have its value for application. With the deepening of research, its value will be acknowledged much more by people. Preserving people's own cord blood hematopoietic stem cells when economically reasonable is not only a way for individual back up or insurance, but also a promising application for relatives or donations from public cord blood bank.
Umbilical cord blood transplantation has saved lives of many patients. Although some people think that there’s minor risk of suffering from above mentioned diseases, in the long
run, cord blood can be used as preventive measure. Umbilical cord blood transplantation has saved lives of many patients. Although some people think that there’s minor risk of suffering from above mentioned diseases, in the long
run, cord blood can be used as a preventive measure. Therefore, storing cord blood is significant from the clinical perspective.
In China, 5 million patients suffered from hematological diseases are waiting for the transplantation of hematopoietic stem cells, and the numbers are growing with the speed of 40,000 patients per year with half of whom are children. However, only about 0.03% of patients are lucky enough to be treated with hematopoietic stem cells every year. This cruel fact shows that every drip of cord blood whether to be donated or saved for ourselves, can alleviate the current serious situation and offer patients hope of second life.